tert-butyl {3-[4-(8-chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)piperazin-1-yl]propyl}carbamate | 1357146-49-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: tert-butyl {3-[4-(8-chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)piperazin-1-yl]propyl}carbamate
• 英文别名: tert-butyl N-[3-[4-(3-chloro-11H-benzo[b][1,4]benzodiazepin-6-yl)piperazin-1-yl]propyl]carbamate
• CAS: 1357146-49-6
• 化学式: C₂₅H₃₂ClN₅O₂
• 分子量: 470.014
• InChiKey: PEBGWMJZXSACQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  69.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl {3-[4-(8-chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)piperazin-1-yl]propyl}carbamate 在 三氟乙酸 、 potassium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.0h， 以94%的产率得到3-[4-(8-chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)piperazin-1-yl]propan-1-amine
  参考文献：
  名称：

  Homobivalent Ligands of the Atypical Antipsychotic Clozapine: Design, Synthesis, and Pharmacological Evaluation

  摘要：

  To date all typical and atypical antipsychotics target the dopamine D-2 receptor. Clozapine represents the best-characterized atypical antipsychotic, although it displays only moderate (submicromolar) affinity for the dopamine D-2 receptor. Herein, we present the design, synthesis, and pharmacological evaluation of three series of homobivalent ligands of clozapine, differing in the length and nature of the spacer and the point of attachment to the pharmacophore. Attachment of the spacer at the N4' position of clozapine yielded a series of homobivalent ligands that displayed spacer-length-dependent gains in affinity and activity for the dopamine D-2 receptor. The 16 and 18 atom spacer bivalent ligands were the highlight compounds, displaying marked low nanomolar receptor binding affinity (1.41 and 1.35 nM, respectively) and functional activity (23 and 44 nM), which correspond to significant gains in affinity (75- and 79-fold) and activity (9- and 5-fold) relative to the original pharmacophore, clozapine. As such these ligands represent useful tools with which to investigate dopamine receptor dimerization and the atypical nature of clozapine.

  DOI：

  10.1021/jm201420s
• 作为产物：
  描述：

  氯氮平 在 1-氯乙基氯甲酸酯 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 1,2-dicholoroethane 、 乙腈 为溶剂， 反应 27.5h， 生成 tert-butyl {3-[4-(8-chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)piperazin-1-yl]propyl}carbamate
  参考文献：
  名称：

  Homobivalent Ligands of the Atypical Antipsychotic Clozapine: Design, Synthesis, and Pharmacological Evaluation

  摘要：

  To date all typical and atypical antipsychotics target the dopamine D-2 receptor. Clozapine represents the best-characterized atypical antipsychotic, although it displays only moderate (submicromolar) affinity for the dopamine D-2 receptor. Herein, we present the design, synthesis, and pharmacological evaluation of three series of homobivalent ligands of clozapine, differing in the length and nature of the spacer and the point of attachment to the pharmacophore. Attachment of the spacer at the N4' position of clozapine yielded a series of homobivalent ligands that displayed spacer-length-dependent gains in affinity and activity for the dopamine D-2 receptor. The 16 and 18 atom spacer bivalent ligands were the highlight compounds, displaying marked low nanomolar receptor binding affinity (1.41 and 1.35 nM, respectively) and functional activity (23 and 44 nM), which correspond to significant gains in affinity (75- and 79-fold) and activity (9- and 5-fold) relative to the original pharmacophore, clozapine. As such these ligands represent useful tools with which to investigate dopamine receptor dimerization and the atypical nature of clozapine.

  DOI：

  10.1021/jm201420s

文献信息

• An Integrated Approach toward NanoBRET Tracers for Analysis of GPCR Ligand Engagement
  作者：Michael P. Killoran、Sergiy Levin、Michelle E. Boursier、Kristopher Zimmerman、Robin Hurst、Mary P. Hall、Thomas Machleidt、Thomas A. Kirkland、Rachel Friedman Ohana

  DOI：10.3390/molecules26102857

  日期：——

  Gaining insight into the pharmacology of ligand engagement with G-protein coupled receptors (GPCRs) under biologically relevant conditions is vital to both drug discovery and basic research. NanoLuc-based bioluminescence resonance energy transfer (NanoBRET) monitoring competitive binding between fluorescent tracers and unmodified test compounds has emerged as a robust and sensitive method to quantify ligand engagement with specific GPCRs genetically fused to NanoLuc luciferase or the luminogenic HiBiT peptide. However, development of fluorescent tracers is often challenging and remains the principal bottleneck for this approach. One way to alleviate the burden of developing a specific tracer for each receptor is using promiscuous tracers, which is made possible by the intrinsic specificity of BRET. Here, we devised an integrated tracer discovery workflow that couples machine learning-guided in silico screening for scaffolds displaying promiscuous binding to GPCRs with a blend of synthetic strategies to rapidly generate multiple tracer candidates. Subsequently, these candidates were evaluated for binding in a NanoBRET ligand-engagement screen across a library of HiBiT-tagged GPCRs. Employing this workflow, we generated several promiscuous fluorescent tracers that can effectively engage multiple GPCRs, demonstrating the efficiency of this approach. We believe that this workflow has the potential to accelerate discovery of NanoBRET fluorescent tracers for GPCRs and other target classes.

  获取有关配体在生物相关条件下与G蛋白偶联受体（GPCRs）相互作用的药理学见解对于药物发现和基础研究至关重要。基于NanoLuc的生物发光共振能量转移（NanoBRET）监测荧光示踪剂与未修改的测试化合物之间的竞争结合已经成为一种强大而敏感的方法，用于量化与特定GPCRs遗传融合到NanoLuc荧光酶或发光HiBiT肽的配体相互作用。然而，开发荧光示踪剂通常具有挑战性，并且仍然是该方法的主要瓶颈。减轻为每个受体开发特定示踪剂的负担的一种方法是使用多功能示踪剂，这是由BRET的固有特异性所实现的。在这里，我们设计了一种集成示踪剂发现工作流程，将机器学习引导的体外筛选具有对GPCRs显示多功能结合的支架与合成策略的混合相结合，以快速生成多个示踪剂候选物。随后，这些候选物在HiBiT标记的GPCRs库中进行了NanoBRET配体结合筛选的结合评估。利用这种工作流程，我们生成了几种可以有效与多个GPCRs相互作用的多功能荧光示踪剂，展示了这种方法的效率。我们相信这种工作流程有潜力加速发现用于GPCRs和其他靶标类别的NanoBRET荧光示踪剂。
• [EN] BROAD SPECTRUM GPCR BINDING AGENTS<br/>[FR] AGENTS DE LIAISON AUX RCPG À LARGE SPECTRE
  申请人：PROMEGA CORP

  公开号：WO2020117954A3

  公开（公告）日：2020-07-23
• BROAD SPECTRUM GPCR BINDING AGENTS
  申请人：Promega Corporation

  公开号：US20200200765A1

  公开（公告）日：2020-06-25

  Provided herein are broad-spectrum G-Protein coupled receptor (GPCR) binding agents, detectable/isolatable compounds comprising such binding agents (e.g., broad-spectrum GPCR binding agents linked to a functional element and/or solid surface), and methods of use thereof for the detection/isolation of GPCRs.